Beta Bionics Q4 revenue up 145% to $20.4M; FY2025 guidance $80-85M

Beta Bionics, Inc.

Q4 net sales $20.4M (+145% YoY); FY2024 net sales $65.1M (+443% YoY). Installed base 15,298 users (+564%).
Operating loss Q4 $13.0M (neg 64% of sales); net loss $18.1M. Full year operating loss $45.3M.
Cash $103.6M at Dec 31, 2024; raised ~$206M net from IPO/private placement in Jan 2025.
FY2025 guidance: revenue $80-85M, >20% new patient starts from PBP channel, gross margin ≥50%.
Prime Therapeutics added iLet to national commercial formulary; first-to-market integration with Abbott FreeStyle Libre 3 Plus.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.